San Francisco – December 19, 2025 Cooley advised BioMarin Pharmaceutical, a leading global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions, on an approximately $3.7 billion bridge financing commitment in connection with its acquisition of Amicus Therapeutics.

The Cooley team advising BioMarin on the financing was led by partners Michael Tollini and Addison Pierce and included partners Chadwick Mills and Julia Boesch, of counsel Siana Lowrey, and associate Charles Watkins.

Cooley has represented BioMarin for 10+ years, including in its definitive agreement to acquire Inozyme Pharma in May 2025, its $600 million revolving credit facility in August 2024, a securities class action win before the US Court of Appeals for the Ninth Circuit in February 2024, its $550 million offering of 1.25% senior subordinated convertible notes due 2027 in May 2020, its licensing agreement with Allievex in October 2019, its $720 million follow-on offering in July 2018, its $450 million offering of 0.599% senior subordinated convertible notes due 2024 in August 2017, and its $720 million follow-on offering in September 2016.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.